Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

MIF functional polymorphisms (-794 CATT5-8 and -173 G>C) are associated with MIF serum levels, severity and progression in male multiple sclerosis from western Mexican population.

Castañeda-Moreno VA, De la Cruz-Mosso U, Torres-Carrillo N, Macías-Islas MA, Padilla-De la Torre O, Mireles-Ramírez MA, González-Pérez O, Ruiz-Sandoval JL, Huerta M, Trujillo X, Ortuño-Sahagún D, Jf MV.

J Neuroimmunol. 2018 Apr 10. pii: S0165-5728(17)30593-3. doi: 10.1016/j.jneuroim.2018.04.006. [Epub ahead of print]

PMID:
29661540
2.

Mediational Model of Multiple Sclerosis Impairments, Family Needs, and Caregiver Mental Health in Guadalajara, Mexico.

Mickens MN, Perrin PB, Aguayo A, Rabago B, Macías-Islas MA, Arango-Lasprilla JC.

Behav Neurol. 2018 Jan 17;2018:8929735. doi: 10.1155/2018/8929735. eCollection 2018.

3.

Effect of fish and olive oil on mitochondrial ATPase activity and membrane fluidity in patients with relapsing-remitting multiple sclerosis treated with interferon beta 1-b.

Torres-Sánchez ED, Pacheco-Moisés FP, Macias-Islas MA, Morales-Sánchez EW, Ramírez-Ramírez V, Celis de la Rosa AJ, Cid-Hernández M, Sorto-Gómez TE, Ortiz GG.

Nutr Hosp. 2018 Jan 12;35(1):162-168. doi: 10.20960/nh.1084.

4.

Absence of the tag polymorphism for the risk haplotype HLA-DR2 for multiple sclerosis in Wixárika subjects from Mexico.

González-Enríquez GV, Torres-Mendoza BM, Márquez-Pedroza J, Macías-Islas MA, Ortiz GG, Cruz-Ramos JA.

Immunogenetics. 2018 Feb 3. doi: 10.1007/s00251-018-1052-8. [Epub ahead of print]

PMID:
29397401
5.

Effect of melatonin administration on cyclooxygenase-2 activity, serum levels of nitric oxide metabolites, lipoperoxides and glutathione peroxidase activity in patients with Parkinson’s disease

Ortiz GG, Moráles-Sánchez EW, Pacheco-Moisés FP, Jiménez-Gil FJ, Macías-Islas MA, Mireles-Ramírez MA, González-Usigli H.

Gac Med Mex. 2017;153(Supl. 2):S72-S81. doi: 10.24875/GMM.M000008. Spanish.

6.

Environmental noise exposure modifies astrocyte morphology in hippocampus of young male rats.

Huet-Bello O, Ruvalcaba-Delgadillo Y, Feria-Velasco A, González-Castañeda RE, Garcia-Estrada J, Macias-Islas MA, Jauregui-Huerta F, Luquin S.

Noise Health. 2017 Sep-Oct;19(90):239-244. doi: 10.4103/nah.NAH_97_16.

7.

Effect of fish oil on glutathione redox system in multiple sclerosis.

Sorto-Gomez TE, Ortiz GG, Pacheco-Moises FP, Torres-Sanchez ED, Ramirez-Ramirez V, Macias-Islas MA, de la Rosa AC, Velázquez-Brizuela IE.

Am J Neurodegener Dis. 2016 Jun 1;5(2):145-51. eCollection 2016.

8.

Biological and nonbiological complex drugs for multiple sclerosis in Latin America: regulations and risk management.

Carrá A, Macías Islas MA, Tarulla A, Bichuetti DB, Finkelsztejn A, Fragoso YD, Árcega-Revilla R, Cárcamo Rodríguez C, Durán JC, Bonitto JG, León R, Oehninger Gatti C, Orozco G, Vizcarra Escobar D.

Expert Rev Neurother. 2015 Jun;15(6):597-600. doi: 10.1586/14737175.2015.1042456. Epub 2015 Apr 30.

PMID:
25924772
9.

Role of the blood-brain barrier in multiple sclerosis.

Ortiz GG, Pacheco-Moisés FP, Macías-Islas MÁ, Flores-Alvarado LJ, Mireles-Ramírez MA, González-Renovato ED, Hernández-Navarro VE, Sánchez-López AL, Alatorre-Jiménez MA.

Arch Med Res. 2014 Nov;45(8):687-97. doi: 10.1016/j.arcmed.2014.11.013. Epub 2014 Nov 26. Review.

PMID:
25431839
10.

Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Ziemssen T, Bajenaru OA, Carrá A, de Klippel N, Correia de Sá J, Edland A, Frederiksen JL, Heinzlef O, Karageorgiou KE, Lander Delgado RH, Landtblom AM, Macías Islas MA, Tubridy N, Gilgun-Sherki Y.

J Neurol. 2015 Jan;262(1):248. doi: 10.1007/s00415-014-7565-7. No abstract available.

11.

A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.

Ziemssen T, Bajenaru OA, Carrá A, de Klippel N, de Sá JC, Edland A, Frederiksen JL, Heinzlef O, Karageorgiou KE, Lander Delgado RH, Landtblom AM, Macías Islas MA, Tubridy N, Gilgun-Sherki Y.

J Neurol. 2014 Nov;261(11):2101-11. doi: 10.1007/s00415-014-7446-0. Epub 2014 Aug 14. Erratum in: J Neurol. 2015 Jan;262(1):248.

12.

Prevalence of Dementia, Emotional State and Physical Performance among Older Adults in the Metropolitan Area of Guadalajara, Jalisco, Mexico.

Velázquez-Brizuela IE, Ortiz GG, Ventura-Castro L, Arias-Merino ED, Pacheco-Moisés FP, Macías-Islas MA.

Curr Gerontol Geriatr Res. 2014;2014:387528. doi: 10.1155/2014/387528. Epub 2014 Mar 27.

13.

Novel Point Mutations and A8027G Polymorphism in Mitochondrial-DNA-Encoded Cytochrome c Oxidase II Gene in Mexican Patients with Probable Alzheimer Disease.

Loera-Castañeda V, Sandoval-Ramírez L, Pacheco Moisés FP, Macías-Islas MÁ, Alatorre Jiménez MA, González-Renovato ED, Cortés-Enríquez F, Célis de la Rosa A, Velázquez-Brizuela IE, Ortiz GG.

Int J Alzheimers Dis. 2014;2014:794530. doi: 10.1155/2014/794530. Epub 2014 Feb 18.

14.

Immunology and oxidative stress in multiple sclerosis: clinical and basic approach.

Ortiz GG, Pacheco-Moisés FP, Bitzer-Quintero OK, Ramírez-Anguiano AC, Flores-Alvarado LJ, Ramírez-Ramírez V, Macias-Islas MA, Torres-Sánchez ED.

Clin Dev Immunol. 2013;2013:708659. doi: 10.1155/2013/708659. Epub 2013 Sep 24. Review.

15.

Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.

Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators.

JAMA Intern Med. 2013 Oct 14;173(18):1682-92.

PMID:
23939297
16.

Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b.

Ramirez-Ramirez V, Macias-Islas MA, Ortiz GG, Pacheco-Moises F, Torres-Sanchez ED, Sorto-Gomez TE, Cruz-Ramos JA, Orozco-Aviña G, Celis de la Rosa AJ.

Oxid Med Cell Longev. 2013;2013:709493. doi: 10.1155/2013/709493. Epub 2013 Jun 18.

17.

Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis.

Macías-Islas MA, Soria-Cedillo IF, Velazquez-Quintana M, Rivera VM, Baca-Muro VI, Lemus-Carmona EA, Chiquete E.

Acta Neurol Belg. 2013 Dec;113(4):415-20. doi: 10.1007/s13760-013-0200-z. Epub 2013 May 14.

PMID:
23670405
18.

Neural restrictive silencer factor and choline acetyltransferase expression in cerebral tissue of Alzheimer's Disease patients: A pilot study.

González-Castañeda RE, Sánchez-González VJ, Flores-Soto M, Vázquez-Camacho G, Macías-Islas MA, Ortiz GG.

Genet Mol Biol. 2013 Mar;36(1):28-36. doi: 10.1590/S1415-47572013000100005. Epub 2013 Mar 4.

19.

Prevalence of Cognitive Impairment and Depression among a Population Aged over 60 Years in the Metropolitan Area of Guadalajara, Mexico.

Ortiz GG, Arias-Merino ED, Flores-Saiffe ME, Velázquez-Brizuela IE, Macías-Islas MA, Pacheco-Moisés FP.

Curr Gerontol Geriatr Res. 2012;2012:175019. doi: 10.1155/2012/175019. Epub 2012 Dec 3.

20.

Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents.

Finkelsztejn A, Gabbai AA, Fragoso YD, Carrá A, Macías-Islas MA, Arcega-Revilla R, García-Bonitto J, Oehninger-Gatti CL, Orozco-Escobar G, Tarulla A, Vergara F, Vizcarra D.

Arq Neuropsiquiatr. 2012 Oct;70(10):799-806.

Supplemental Content

Loading ...
Support Center